The reaffirmation of a Buy rating and a price target of $11 by a reputable analyst firm like HC Wainwright & Co. could instill confidence among investors and potentially lead to a positive short-term impact on Ikena Oncology's stock price. The analyst's continued support suggests a belief in the company's value and prospects, which can be a positive signal to the market.